Literature DB >> 23793787

Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies.

Raffaele Iorio1, Valentina Damato, Massimiliano Mirabella, Amelia Evoli, Alessandro Marti, Domenico Plantone, Giovanni Frisullo, Anna Paola Batocchi.   

Abstract

Longitudinally extensive transverse myelitis (LETM) is a characteristic feature of Neuromyelitis Optica (NMO), but it can also occur in several other inflammatory diseases of the central nervous system (CNS). An IgG autoantibody that binds to aquaporin-4 (AQP4), the predominant water channel of the CNS, is a reliable biomarker of the NMO spectrum disorders, and if detected predicts the recurrence of the myelitis. In this study, we compared the clinical and neuroimaging characteristics of AQP4-IgG+ and AQP4-IgG- LETM patients. Thirty-seven first-ever LETM patients were retrospectively evaluated and divided into two groups according to the presence of AQP4 autoantibodies. AQP4-IgG was detected in the serum and in the cerebrospinal fluid of sixteen patients. The female to male ratio was higher in AQP4-IgG+ patients. Intractable nausea and vomiting and paroxysmal tonic spasms often accompanied the LETM in AQP4-IgG+ patients. T2-weighted spinal cord MRI revealed that inflammatory lesions extending into the brainstem and involving the central grey matter occurred more frequently in AQP4-IgG+ LETM patients. Hypointense lesions on T1-weighted spinal cord MRI were detected more frequently in the seropositive group, and their presence correlated with attack severity. In conclusion, this study provides clinical and spinal cord neuroimaging clues that can help distinguishing AQP4-IgG+ LETM patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23793787     DOI: 10.1007/s00415-013-6997-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  T F Scott; E M Frohman; J De Seze; G S Gronseth; B G Weinshenker
Journal:  Neurology       Date:  2011-12-07       Impact factor: 9.910

2.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

3.  Intractable vomiting as the initial presentation of neuromyelitis optica.

Authors:  Metha Apiwattanakul; Bogdan F Popescu; Marcelo Matiello; Brian G Weinshenker; Claudia F Lucchinetti; Vanda A Lennon; Andrew McKeon; Adam F Carpenter; Gary M Miller; Sean J Pittock
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

4.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.

Authors:  M A van Walderveen; W Kamphorst; P Scheltens; J H van Waesberghe; R Ravid; J Valk; C H Polman; F Barkhof
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

5.  Association between paroxysmal tonic spasms and neuromyelitis optica.

Authors:  Nida Usmani; Gurdesh Bedi; Byron L Lam; William A Sheremata
Journal:  Arch Neurol       Date:  2012-01

6.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

7.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

8.  Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays.

Authors:  Raffaele Iorio; James P Fryer; Shannon R Hinson; Petra Fallier-Becker; Hartwig Wolburg; Sean J Pittock; Vanda A Lennon
Journal:  J Autoimmun       Date:  2012-08-18       Impact factor: 7.094

9.  Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.

Authors:  S R Hinson; S J Pittock; C F Lucchinetti; S F Roemer; J P Fryer; T J Kryzer; V A Lennon
Journal:  Neurology       Date:  2007-10-10       Impact factor: 9.910

10.  T1 hypointensity of the spinal cord in multiple sclerosis.

Authors:  N A Losseff; L Wang; D H Miller; A J Thompson
Journal:  J Neurol       Date:  2001-06       Impact factor: 4.849

View more
  14 in total

1.  Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder.

Authors:  Giorgia Olivieri; Viviana Nociti; Raffaele Iorio; Maria Chiara Stefanini; Francesco Antonio Losavio; Massimiliano Mirabella; Paolo Mariotti
Journal:  Neurol Sci       Date:  2015-08-21       Impact factor: 3.307

Review 2.  Neuro-ophthalmology update.

Authors:  Konrad P Weber; Dominik Straumann
Journal:  J Neurol       Date:  2013-09-26       Impact factor: 4.849

3.  Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions.

Authors:  Yanqiang Wang; Lei Zhang; Bingjun Zhang; Yongqiang Dai; Zhuang Kang; Ciyong Lu; Wei Qiu; Xueqiang Hu; Zhengqi Lu
Journal:  J Neurol       Date:  2014-03-09       Impact factor: 4.849

Review 4.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

5.  Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.

Authors:  Maria Sepúlveda; Nuria Sola-Valls; Domingo Escudero; Bojan Rojc; Manuel Barón; Luis Hernández-Echebarría; Begoña Gómez; Josep Dalmau; Albert Saiz; Francesc Graus
Journal:  Mult Scler       Date:  2017-09-18       Impact factor: 6.312

Review 6.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

Review 7.  MRI characteristics of neuromyelitis optica spectrum disorder: an international update.

Authors:  Ho Jin Kim; Friedemann Paul; Marco A Lana-Peixoto; Silvia Tenembaum; Nasrin Asgari; Jacqueline Palace; Eric C Klawiter; Douglas K Sato; Jérôme de Seze; Jens Wuerfel; Brenda L Banwell; Pablo Villoslada; Albert Saiz; Kazuo Fujihara; Su-Hyun Kim
Journal:  Neurology       Date:  2015-02-18       Impact factor: 9.910

8.  Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders.

Authors:  G Orman; K Y Wang; Y Pekcevik; C B Thompson; M Mealy; M Levy; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-16       Impact factor: 3.825

Review 9.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

Review 10.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.